全球非电离乳腺成像市场 – 行业趋势及 2029 年预测

全球非电离乳腺成像市场分析和规模

根据世界卫生组织 (WHO) 的数据，乳腺癌是女性中第二大常见癌症，全球每年诊断出超过 20 万例新发癌症病例。乳腺癌发病率的上升进一步提高了全球对乳腺癌早期检测的认识。因此，政府的支持性举措有助于传播有关癌症风险因素、预防措施和早期检测的意识。因此，这些增长决定因素将在预测期内推动市场扩张。

• 2021 年非电离乳腺成像市场价值为 40.2 亿美元，预计到 2029 年将达到 77.7 亿美元，2022-2029 年复合年增长率为 8.60%。由于“乳腺超声”的辐射暴露风险较低，且具有多种优势，例如能够检测病变、区分囊肿和实体肿块以及检测血管中的血流，因此在预测期内，“乳腺超声”占据非电离乳腺成像市场的最大类型细分市场。Data Bridge 市场研究团队策划的市场报告包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

全球非电离乳腺成像市场定义

乳腺成像是诊断放射学的一个分支学科，涉及对乳腺进行成像以进行诊断或筛查。乳腺成像技术用于研究女性乳腺组织，以诊断乳腺癌和其他乳腺相关疾病。一些最受欢迎的乳腺成像检查包括乳房 X 光检查、乳腺磁共振成像 (MRI) 和超声波。

报告范围和市场细分

Non-Ionizing Breast Imaging Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

Drivers

• Growing Requirement for Diagnosis

The rising prevalence of breast cancer is the most significant factor driving the growth for this market as it further requires diagnosis and screening. The increasing population of women who are more susceptible to breast cancer is also projected to bolster the market's growth.

Furthermore, the expanding healthcare sector along with the rise in demand for early diagnosis are also expected to fuel market growth. Moreover, the increasing number of screening programs, as well as rising number of conferences and symposiums focusing on spreading awareness about the benefits of early screening and diagnosis, also cushions the market's growth within the forecasted period.

Opportunities

• Improving Reimbursement, Funding and Investments

Moreover, the improving reimbursement scenario and increase in funding from private and government organizations for the development of healthcare infrastructure are estimated to generate lucrative opportunities for the market. The growing government and private investments to meet the increasing demand for breast cancer screening will further offer numerous growth opportunities for the market.

Restraints/Challenges Global Non-Ionizing Breast Imaging Market

• High Costs

On the other hand, the high cost required for detecting breast cancer is expected to obstruct market growth.

• Effects of Radiation

The adverse effects from exposure to radiation leads to the lesser population turn up for the procedure. This factor is estimated to impede the overall growth of the market.

• Strict Regulations

Also, the stringent regulatory approval procedures are projected to challenge the non-ionizing breast imaging market in the forecast period of 2022-2029.

This non-ionizing breast imaging market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-ionizing breast imaging market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post Covid-19 Impact on Non-Ionizing Breast Imaging Market

The emergence of COVID-19 pandemic put a strain on healthcare systems all around the world. The non-ionizing breast imaging market was largely impacted by the outbreak of COVID-19.

During the pandemic, the imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak, led to halt of various operations, supply chain disruptions, stifling business growth, technology event cancellations, suspensions of new developments and has affected the overall production and sales further limits the industry's expansion. The implementation of lockdown resulted in a decrease in the number of patient visits for other diseases such as cancer and diabetes. According to the Eurasian Journal of Medical Investigation (EJMI), between April and July 2020, there was a 41.7 percent -64.4 percent reduction in the number of breast imaging modalities. The mammography technology showed the most significant decline. The mammography technology showed the most significant decline.

Recent Developments

• In April 2021, Seno Medical's Imagio P200003 Breast Imaging System has been authorized by the US Food and Drug Administration (FDA). The Imagio Breast Imaging System images breast tissues using both optoacoustic (OA) and ultrasound (US) technology to assist clinicians in examining breast abnormalities.
• In April 2021, Dilon Technologies Inc., the owner of the Navigator Gamma Probes and a world-class global leader in breast cancer therapy and detection, has acquired all of Dune Medical's assets, including Dune Medical's "MarginProbe essentially."

Global Non-Ionizing Breast Imaging Market Scope

The non-ionizing breast imaging market is segmented on the basis of type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Breast Ultrasound
• Breast MRI
• Automated Whole-breast Ultrasound (AWBU)
• Breast thermography
• Electric Impedance Tomography
• Optical Imaging

On the basis of type, the non-ionizing breast imaging market is segmented into breast ultrasound, breast MRI, automated whole-breast ultrasound (AWBU), breast thermography, electric impedance tomography and optical imaging. The breast ultrasound segment is projected to account for the largest share owing to the lower risk of exposure to radiation and the various benefits such as the ability to detect lesions and the ability to differentiate between a cyst and a solid mass and the detection of blood flow through vessels.

End User

• Hospital
• Diagnostic Imaging Centre
• Others

On the basis of end user, the non-ionizing breast imaging market is bifurcated into hospital, diagnostic imaging centre and others.

Non-Ionizing Breast Imaging Market Regional Analysis/Insights

The non-ionizing breast imaging market is analyzed and market size insights and trends are provided by country, type and end user as referenced above.

The countries covered in the non-ionizing breast imaging market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the non-ionizing breast imaging market because of the substantial research and development expenditure, well-established healthcare infrastructures, widespread acceptance of advanced medical technologies and superior reimbursement facilities within the region.

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the rising government and non-government initiatives to prevent breast cancer coupled with the constant development in the healthcare infrastructures within the region.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

非电离乳腺成像市场还为您提供了每个国家/地区资本设备医疗保健支出增长、非电离乳腺成像市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对非电离乳腺成像市场的影响的详细市场分析。数据适用于 2010-2020 年的历史时期。

竞争格局和非电离乳腺成像市场份额分析

非电离乳腺成像市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对非电离乳腺成像市场的关注有关。

非电离乳腺成像市场的一些主要参与者包括

• Hologic, Inc.（美国）
• 通用电气（美国）
• 西门子（德国）
• Koninklijke Philips NV（荷兰）
• 富士控股株式会社（日本）
• 佳能公司（日本）
• Aurora Healthcare US Corp.（美国）
• Allengers（印度）
• Dilon Medical Technologies, Inc.（美国）
• 西门子（德国）
• Planmed Oy.（芬兰）
• Delphinus Medical Technologies, Inc.（美国）
• Micrima Limited（英国）
• CMR Naviscan Corporation（美国）、SuperSonic Imagine（法国）
• Carestream Health（美国）

研究方法：全球非电离乳腺成像市场

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息，请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询 https://www.databridgemarketresearch.com/zh/speak-to-analyst/?dbmr=global-non-ionizing-breast-imaging-market

SKU-67991